• Publications
  • Influence
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
TLDR
Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved. Expand
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
TLDR
After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. Expand
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
TLDR
It is reported that AMN107 and BMS-354825 are 20-fold and 325-fold more potent than imatinib against cells expressing wild-type Bcr-Abl and that similar improvements are maintained for allImatinib-resistant mutants tested, with the exception of T315I. Expand
The molecular biology of chronic myeloid leukemia.
TLDR
The discovery of the Philadelphia (Ph) chromosome in 19601 as the first consistent chromosomal abnormality associated with a specific type of leukemia was a breakthrough in cancer biology and took 13 years to be published. Expand
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
TLDR
Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk. Expand
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
TLDR
Ruxolitinib provided significant clinical benefits in patients with myel ofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival. Expand
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
TLDR
It is recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be 400 mg IM daily and the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT) is confirmed. Expand
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
TLDR
Design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants, and clinical evaluation ofAP24534 as a pan-BCR-ABl inhibitor for treatment of CML are reported. Expand
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
TLDR
The preclinical and clinical development of imatinib for the therapy of CML, resistance and strategies that may help to eliminate resistant or residual leukemia are reviewed. Expand
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
TLDR
Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. Expand
...
1
2
3
4
5
...